# Hangzhou Chance Pharmaceuticals Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-chance-pharmaceuticals-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.chancepharmaceuticals.com
- Total disclosed funding: $40M
- Latest round: Series C (Jan 4, 2022)
- Investors on record: 8

## About

Hangzhou Chance Pharmaceuticals Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative inhalation therapies for respiratory and central nervous system disorders.Founded in 2015 and headquartered in Hangzhou, China, Hangzhou Chance Pharmaceuticals specializes in biopharmaceutical development. The company has executed 6 deals and recently engaged in a Series C funding round, raising USD 30.00 mn led by Lapam Capital. This funding is part of a strategy to enhance its clinical trial capabilities.Hangzhou Chance Pharmaceuticals is a clinical-stage biopharmaceutical firm that discovers and develops novel inhalation medications. Its advanced products include inhalation devices and formulations aimed at improving treatments for respiratory and central nervous system diseases, utilizing a proprietary virtual reality drug development platform. The company serves healthcare providers and pharmaceutical partners, primarily in China, with plans for expansion into other global markets.Hangzhou Chance Pharmaceuticals generates revenue through strategic partnerships in the biopharmaceutical sector, focusing on innovative inhalation therapies. The company engages in B2B transactions, providing inhalation products to healthcare institutions and pharmaceutical distributors, with pricing structures negotiated based on volume or commitments.In March 2025, Hangzhou Chance Pharmaceuticals raised USD 30.00 mn in a Series C funding round from investors including Hangzhou Heda Financial Services and Qihang Venture. This funding will support the financing of clinical trials as the company seeks to advance its inhalation therapies. Plans include launching additional products and expanding into international markets where respiratory and central nervous system disorders are prevalent.

## Funding rounds

- Series C, Jan 4, 2022 — Fortune Capital
- Series C, Oct 10, 2021, $30M — CMS Capital, China Merchants Zhiyuan Capital Investment, Lapam Capital, Shenzhen Guozhong Venture Capital, Heda Ventures
- Series A, Jan 1, 2018, $8.5M — Kaitai Capital, Delian Capital, Shenzhen Guozhong Venture Capital
- Angel, Apr 1, 2016, $1.5M — Delian Capital

## Investors

- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Angel, Series A
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A, Series C
- CMS Capital — Series C
- China Merchants Zhiyuan Capital Investment — Series C
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series C
- Heda Ventures (https://capitalatlas.ai/funds/heda-ventures) — Series C
- Fortune Capital — Series C